Results 251 to 260 of about 5,634,975 (396)

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Epidemiology of Polypharmacy and Potential Drug–Drug Interactions Among Pediatric Patients in ICUs of U.S. Children’s Hospitals*

Pediatric Critical Care Medicine, 2016
D. Dai, J. Feinstein, W. Morrison, A. Zuppa, C. Feudtner   +4 more
semanticscholar   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Interaction of Drugs with Polymers. III. Phase Separation of Polyacids by O-Benzoylthiamine Disulfide Hydrochloride and Gastrointestinal Absorption of O-Benzoylthiamine Disulfide-Polyacid Complexes

, 1970
Nobuo Tanaka, GOICHI HIRATA, Isamu Utsumi   +2 more
openalex   +2 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Mapping the Global Research on Drug-Drug Interactions: A Multidecadal Evolution Through AI-Driven Terminology Standardization. [PDF]

Bioengineering (Basel)
Radu AF, Radu A, Tit DM, Bungau G, Negru PA.   +4 more
europepmc   +1 more source

A Manual of Adverse Drug Interactions [PDF]

, 1976
A. R. M.
openalex   +1 more source

Identifying prognostic targets in metastatic prostate cancer beyond AR

FEBS Open Bio, EarlyView.
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng, Eric Feng, Tracy Berg, Isabella S. Nguyen, Lilac G. Nguyen, William Chen, Meng Zhang, David Quigley, Marina Sharifi, Haolong Li, Ilsa Coleman, Peter S. Nelson, Martin Sjöström, Shuang G. Zhao   +13 more
wiley   +1 more source

The Need for Translational Research on Drug-drug Interactions [PDF]

, 2012
Flockhart, David A., Hennessy, Sean
core   +1 more source

Unveiling Drug-Drug Interactions in Dental Patients: A Retrospective Real-World Study. [PDF]

Dent J (Basel)
Colibășanu D, Ardelean SM, Goldiș FD, Drăgoi MM, Vasii SO, Maksimović T, Colibășanu Ș, Șoica C, Udrescu L.   +8 more
europepmc   +1 more source